Literature DB >> 28739659

The Stress-Sensing TORC2 Complex Activates Yeast AGC-Family Protein Kinase Ypk1 at Multiple Novel Sites.

Kristin L Leskoske1,2, Françoise M Roelants1,2, Maria Nieves Martinez Marshall1,2, Jennifer M Hill1,2, Jeremy Thorner3,4.   

Abstract

Yeast (Saccharomyces cerevisiae) target of rapamycin (TOR) complex 2 (TORC2) is a multi-subunit plasma membrane-associated protein kinase and vital growth regulator. Its essential functions are exerted via phosphorylation and stimulation of downstream protein kinase Ypk1 (and its paralog Ypk2). Ypk1 phosphorylates multiple substrates to regulate plasma membrane lipid and protein composition. Ypk1 function requires phosphorylation of Thr504 in its activation loop by eisosome-associated Pkh1 (and its paralog Pkh2). For cell survival under certain stresses, however, Ypk1 activity requires further stimulation by TORC2-mediated phosphorylation at C-terminal sites, dubbed the "turn" (Ser644) and "hydrophobic" (Thr662) motifs. Here we show that four additional C-terminal sites are phosphorylated in a TORC2-dependent manner, collectively defining a minimal consensus. We found that the newly identified sites are as important for Ypk1 activity, stability, and biological function as Ser644 and Thr662. Ala substitutions at the four new sites abrogated the ability of Ypk1 to rescue the phenotypes of Ypk1 deficiency, whereas Glu substitutions had no ill effect. Combining the Ala substitutions with an N-terminal mutation (D242A), which has been demonstrated to bypass the need for TORC2-mediated phosphorylation, restored the ability to complement a Ypk1-deficient cell. These findings provide new insights about the molecular basis for TORC2-dependent activation of Ypk1.
Copyright © 2017 by the Genetics Society of America.

Entities:  

Keywords:  TORC2; Ypk1; homeostasis; mutants; phosphorylation; regulation; stress response

Mesh:

Substances:

Year:  2017        PMID: 28739659      PMCID: PMC5586371          DOI: 10.1534/genetics.117.1124

Source DB:  PubMed          Journal:  Genetics        ISSN: 0016-6731            Impact factor:   4.562


THE eukaryotic plasma membrane (PM) is a highly organized, yet dynamic, structure comprised of specific proteins and several classes of lipids (Simons and Sampaio 2011). The composition and distribution of the lipids in the PM affects many different PM-mediated processes, including endocytosis (Platta and Stenmark 2011), solute transport (Divito and Amara 2009), and signal transduction (Groves and Kuriyan 2010). Eukaryotic cells have evolved, therefore, mechanisms to sense and respond to environmental stresses that affect PM status, such as fluctuations in temperature or osmolarity, and other perturbations, such as sphingolipid limitation, and thereby adjust cell physiology appropriately to maintain homeostasis. Using budding yeast (Saccharomyces cerevisiae) as the experimental organism, it has been shown by us (Roelants , 2017; Muir , 2015; Alvaro ) and others (Berchtold and Walther 2009; Berchtold ; Niles ; Sun ; Fröhlich ) that the large multi-subunit protein kinase target of rapamycin (TOR) complex 2 (TORC2) plays an essential role in sensing and ensuring maintenance of PM homeostasis. TORC2 is one of two evolutionarily conserved TOR-containing protein complexes (Kunz ; Helliwell ; Loewith ; Wedaman ). TORC1 is sensitive to inhibition by rapamycin, whereas TORC2 is normally insensitive to this agent (Jacinto ; Huang and Manning 2009; Betz and Hall 2013; Gaubitz ). In yeast, TORC2 action influences not only reactions that affect PM lipid and protein composition, but also assembly and function of the actin cytoskeleton and actin-driven endocytosis (Bartlett and Kim 2014; Gaubitz ; Roelants ). The catalytic subunit of the TORC1 and TORC2 complexes is a very large TOR polypeptide; metazoans possess a single TOR-encoding gene [human mammalian TOR (mTOR), 2549 residues], whereas budding yeast (Heitman ), fission yeast (Ikai ), and other fungi (Eltschinger and Loewith 2016) encode two TOR proteins, Tor1 and Tor2 (2470 and 2474 residues, respectively, in S. cerevisiae). TORC1 is functional when its catalytic subunit is either Tor1 or Tor2, whereas only Tor2 can serve as the catalytic subunit in TORC2 (Loewith ; Wedaman ). The small β-propeller protein Lst8 binds tightly to and greatly stabilizes the kinase fold in both Tor1 and Tor2 (Yang ; Aylett ; Baretić ), and thus is present in both TORC1 and TORC2. Aside from Lst8, however, the other known subunits in TORC2, namely Avo1, Avo2, Avo3/Tsc11, Bit2, Bit61, Slm1, and Slm2, are all separate and distinct from those in TORC1 (Loewith and Hall 2011; Eltschinger and Loewith 2016). Recent structural, genetic, and biochemical analysis revealed that TORC2 is only insensitive to rapamycin because the C terminus of Avo3 (mammalian homolog is Rictor) blocks the ability of rapamycin-bound FKBP12 (Fpr1 in S. cerevisiae) to bind to the FRB domain of Tor2; deleting a portion of the Avo3 C terminus renders TORC2 sensitive to rapamycin inhibition (Gaubitz ). In a yeast cell where such an truncation is combined with a dominant point mutation () in the FRB domain of Tor1 which blocks its association with rapamycin-Fpr1 (Heitman ), TORC2 can be uniquely inhibited by the addition of rapamycin (Gaubitz ). TORC2 is localized at the PM (Kunz ; Berchtold and Walther 2009; Niles ) and responds to activating perturbations and stresses by directly phosphorylating and thereby stimulating the activity of the downstream AGC-family protein kinase Ypk1 and its paralog Ypk2/Ykr2 (Chen ), which are orthologs of mammalian SGK1 (Casamayor ). An allele of Ypk2 (Ypk2D239A) (Kamada ), or a corresponding Ypk1 allele (Ypk1D242A) (Roelants ), which does not require TORC2-mediated phosphorylation for full activity, rescues the lethality of a temperature-sensitive mutation at restrictive temperatures (Roelants ), indicating that the functions of TORC2 required for viability are all exerted through the action of Ypk1 and/or Ypk2. Because a ∆ strain exhibits no deleterious phenotype (Chen ; Roelants ), Ypk1 alone is able to execute all of the essential functions carried out by these enzymes. Indeed, subsequent analysis of the substrates of Ypk1 has shown that this protein kinase maintains PM homeostasis in multiple ways. Ypk1 reduces the rate of aminoglycerophospholipid flipping from the outer to the inner leaflet of the PM by phosphorylating and inhibiting two protein kinases, Fpk1 and Fpk2, which stimulate the P-type ATPases (“flippases”) that catalyze this inward translocation (Roelants ). Ypk1-mediated inhibition of Fpk1 and Fpk2 also impedes endocytosis by alleviating their inhibition of the protein kinase Akl1, which phosphorylates and blocks the function of several actin patch-associated proteins (Roelants ). Ypk1-mediated phosphorylation also blocks the ability of certain endocytic adaptors (α-arrestins) to promote internalization of integral PM proteins (Alvaro ). Ypk1 increases metabolic flux into sphingolipid synthesis by phosphorylating and thereby relieving the inhibition exerted by two ER-localized tetraspanins (Orm1 and Orm2) on the enzyme (L-serine:palmitoyl-CoA acyltransferase) that catalyzes the first reaction in sphingolipid biosynthesis (Roelants ). Moreover, Ypk1 promotes production of complex sphingolipids by phosphorylating and stimulating the activity of the catalytic subunits (Lac1 and Lag1) of the ceramide synthase complex (Muir ). Unlike other stresses, hyperosmotic shock rapidly inactivates TORC2Ypk1 signaling (Lee ; Muir ). As a result, the inhibitory phosphorylation that Ypk1 normally exerts on the glycerol-3P hydrogenase isoform Gpd1 is alleviated (Lee ) and, similarly, the Ypk1-mediated, channel-opening phosphorylation of the aquaglyceroporin Fps1 is prevented (Muir ), promoting accumulation of intracellular glycerol and cell survival. As observed for other AGC-family protein kinases (Pearce ), activation of Ypk1 is regulated by phosphorylation on residues situated within three conserved sequences. First, phosphorylation of Ypk1 on its activation loop (T-loop) at Thr504 within a conserved T504FCGTPEY motif is required for basal Ypk1 activity; this modification is installed by the eisosome-associated protein kinases Pkh1 and Pkh2 (Roelants , 2004) [orthologs of mammalian 3-phosphoinositide-dependent protein kinase PDK1 (Casamayor )]. However, for cell survival in response to certain stresses (e.g., sphingolipid depletion, heat shock, or hypotonic conditions), Ypk1 activity must be upregulated further by phosphorylation at Thr662 in a shorter conserved sequence F/W-T662-F/Y near its C terminus (Roelants , 2011; Kamada ; Berchtold ; Niles ; Sun ), dubbed the hydrophobic motif. As first revealed by analysis of Ypk2, phosphorylation at the hydrophobic motif is mediated by TORC2, which also phosphorylates another C-terminal site (Ser644 in Ypk1) within another conserved sequence (P-V/I-DS644VV-D/N-E/D), dubbed the turn motif (Roelants ; Kamada ). Thus, TORC2 plays a key role in stimulating Ypk1 activity, thereby allowing cells to cope with these stresses. Given its importance in activating Ypk1 function, we sought to characterize TORC2-mediated phosphorylation of Ypk1 in greater detail. In so doing, we discovered that TORC2 phosphorylates Ypk1 at several previously uncharacterized C-terminal sites distinct from the “classical” turn and hydrophobic motifs. As we document here, phosphorylation at these additional sites is essential for full Ypk1 function. Our findings further suggest that differential phosphorylation by TORC2 at this collection of sites may provide a means for modulating the activity of the population of Ypk1 molecules in a graded manner, thereby allowing for dynamic adjustment of the level of Ypk1 activity to match the immediate needs of the cell.

Materials and Methods

Construction of yeast strains and growth conditions

S. cerevisiae strains used in this study are described in Table 1. Yeast cultures were grown in standard rich (YP) medium or in defined minimal (SC) medium (Sherman ) containing 2% dextrose/glucose and were supplemented with the appropriate nutrients to permit growth of auxotrophs and/or to select for plasmids. For expression of a gene under the control of a galactose-inducible promoter, cells were grown in the appropriate SC medium containing 2% raffinose-0.2% sucrose and induced by addition of 2% galactose for 3 hr. Cultures were grown at 30° unless indicated otherwise.
Table 1

S. cerevisiae strains used in this study

StrainGenotypeSource or reference
BY4741MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0Research Genetics
BY4742MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0Research Genetics
akl1BY4742 akl1∆::KanMXResearch Genetics
atg1BY4742 atg1∆::KanMXResearch Genetics
ark1BY4742 ark1∆::KanMXResearch Genetics
bck1BY4742 bck1∆::KanMXResearch Genetics
bub1BY4742 bub1∆::KanMXResearch Genetics
chk1BY4742 chk1∆::KanMXResearch Genetics
cka1BY4742 cka1∆::KanMXResearch Genetics
cka2BY4742 cka2∆::KanMXResearch Genetics
cmk1BY4742 cmk1∆::KanMXResearch Genetics
cmk2BY4742 cmk2∆::KanMXResearch Genetics
ctk2BY4742 ctk2∆::KanMXResearch Genetics
ctk3BY4742 ctk3∆::KanMXResearch Genetics
dbf2BY4742 dbf2∆::KanMXResearch Genetics
dbf20BY4742 dbf20∆::KanMXResearch Genetics
dun1BY4742 dun1∆::KanMXResearch Genetics
fmp48BY4742 fmp48∆::KanMXResearch Genetics
hrk1BY4742 hrk1∆::KanMXResearch Genetics
ime2BY4742 ime2∆::KanMXResearch Genetics
ire1BY4742 ire1∆::KanMXResearch Genetics
isr1BY4742 isr1∆::KanMXResearch Genetics
kcc4BY4742 kcc4∆::KanMXResearch Genetics
kin1BY4742 kin1∆::KanMXResearch Genetics
hsl1BY4742 hsl1∆::KanMXResearch Genetics
mck1BY4742 mck1∆::KanMXResearch Genetics
mrk1BY4742 mrk1∆::KanMXResearch Genetics
mkk2BY4742 mkk2∆::KanMXResearch Genetics
kns1BY4742 kns1∆::KanMXResearch Genetics
kss1BY4742 kss1∆::KanMXResearch Genetics
mek1BY4742 mek1∆::KanMXResearch Genetics
ptk2BY4742 ptk2∆::KanMXResearch Genetics
rck1BY4742 rck1∆::KanMXResearch Genetics
rim11BY4742 rim11∆::KanMXResearch Genetics
ptk1BY4742 ptk1∆::KanMXResearch Genetics
mkk1BY4742 mkk1∆::KanMXResearch Genetics
npr1BY4742 npr1∆::KanMXResearch Genetics
env7BY4742 env7∆::KanMXResearch Genetics
yck1BY4742 yck1∆::KanMXResearch Genetics
ypk3BY4742 ypk3∆::KanMXResearch Genetics
ssk22BY4742 ssk22∆::KanMXResearch Genetics
ypl150wBY4742 ypl150w∆::KanMXResearch Genetics
yck2BY4742 yck2∆::KanMXResearch Genetics
swe1BY4742 swe1∆::KanMXResearch Genetics
sks1BY4742 sks1∆::KanMXResearch Genetics
frk1BY4742 frk1∆::KanMXResearch Genetics
yck3BY4742 yck3∆::KanMXResearch Genetics
sps1BY4742 sps1∆::KanMXResearch Genetics
sky1BY4742 sky1∆::KanMXResearch Genetics
ypk2BY4742 ypk2∆::KanMXResearch Genetics
rtk1BY4742 rtk1∆::KanMXResearch Genetics
slt2BY4742 slt2∆::KanMXResearch Genetics
skm1BY4742 skm1∆::KanMXResearch Genetics
yak1BY4742 yak1∆::KanMXResearch Genetics
elm1BY4742 elm1∆::KanMXResearch Genetics
sat4BY4742 sat4∆::KanMXResearch Genetics
smk1BY4742 smk1∆::KanMXResearch Genetics
tos3BY4742 tos3∆::KanMXResearch Genetics
tpk2BY4742 tpk2∆::KanMXResearch Genetics
tpk3BY4742 tpk3∆::KanMXResearch Genetics
vhs1BY4742 vhs1∆::KanMXResearch Genetics
pkh3BY4742 pkh3∆::KanMXResearch Genetics
psk2BY4742 psk2∆::KanMXResearch Genetics
tel1BY4742 tel1∆::KanMXResearch Genetics
tor1BY4742 tor1∆::KanMXResearch Genetics
tda1BY4742 tda1∆::KanMXResearch Genetics
ygk3BY4742 ygk3∆::KanMXResearch Genetics
gin4BY4742 gin4∆::KanMXResearch Genetics
kin3BY4742 kin3∆::KanMXResearch Genetics
pbs2BY4742 pbs2∆::KanMXResearch Genetics
pho85BY4742 pho85∆::KanMXResearch Genetics
pkh1BY4742 pkh1∆::KanMXResearch Genetics
prr1BY4742 prr1∆::KanMXResearch Genetics
prr2BY4742 prr2∆::KanMXResearch Genetics
psk1BY4742 psk1∆::KanMXResearch Genetics
ssn3BY4742 ssn3∆::KanMXResearch Genetics
ste20BY4742 ste20∆::KanMXResearch Genetics
tpk1BY4742 tpk1∆::KanMXResearch Genetics
nnk1BY4742 nnk1∆::KanMXResearch Genetics
rck2BY4742 rck2∆::KanMXResearch Genetics
kin2BY4742 kin2∆::KanMXResearch Genetics
ksp1BY4742 ksp1∆::KanMXResearch Genetics
mlp1BY4742 mlp1∆::KanMXResearch Genetics
yJP544BY4741 hog1∆::KanMXThis laboratory
ypk1BY4741 ypk1∆::KanMXResearch Genetics
YFR206BY4742 met150 fpk1∆::KanMX fpk2∆::KanMXRoelants et al. (2010)
fus3BY4742 fus3∆::KanMXResearch Genetics
ste11BY4742 ste11∆::KanMXResearch Genetics
ste7BY4742 ste7∆::KanMXResearch Genetics
cla4BY4742 cla4∆::KanMXResearch Genetics
kk18BY4742 kkq8∆::KanMXResearch Genetics
kin4BY4742 kin4∆::KanMXResearch Genetics
fpk2BY4742 kin82∆::KanMXResearch Genetics
pkp2BY4742 pkp2∆::KanMXResearch Genetics
gcn2BY4742 gcn2∆::KanMXResearch Genetics
ssk2BY4742 ssk2∆::KanMXResearch Genetics
hal5BY4742 hal5∆::KanMXResearch Genetics
ctk1BY4742 ctk1∆::KanMXResearch Genetics
rim15BY4742 rim15∆::KanMXResearch Genetics
vps15BY4742 vps15∆::KanMXResearch Genetics
bud32BY4742 bud32∆::KanMXResearch Genetics
pkh2BY4742 pkh2∆::KanMXResearch Genetics
snf1BY4742 snf1∆::KanMXResearch Genetics
fpk1BY4742 fpk1∆::KanMXResearch Genetics
kin28tsBY4741 kin28ts::KanMXCostanzo et al. (2010)
dbf4tsBY4741 dbf4-3::KanMXCostanzo et al. (2010)
ipl1tsBY4741 ipl1-1::KanMXCostanzo et al. (2010)
cdc28tsBY4741 cdc28-1::KanMXCostanzo et al. (2010)
rio2tsBY4741 rio2-1::KanMXCostanzo et al. (2010)
pkc1tsBY4741 pkc1-1::KanMXCostanzo et al. (2010)
cak1tsBY4741 cak1-23::KanMXCostanzo et al. (2010)
tor2tsBY4741 tor2-29::KanMXCostanzo et al. (2010)
cdc5tsBY4741 cdc5-1::KanMXCostanzo et al. (2010)
cdc7tsBY4741 cdc7-1::KanMXCostanzo et al. (2010)
cdc15tsBY4741 cdc15-2::KanMXCostanzo et al. (2010)
sgv1tsBY4741 sgv1-35::KanMXCostanzo et al. (2010)
TOR1-1 avo3CTTOR1-1 avo31274-1430::HphMX6Gaubitz et al. (2015)
yKL4BY4741 TOR2::HygRMuir et al. (2014)
yNM695BY4741 TOR2::HygR AVO3-3C-3XFLAG::KanMXThis laboratory
yDB344BY4741 3XFlag-Orm1 ypk1∆::KlURA3Roelants et al. (2011)
yAM135-ABY4741 Ypk1(L424A)::URA3 ypk2Δ::KanMX4Muir et al. (2014)

Plasmids and recombinant DNA methods

Plasmids used in this study (Table 2) were constructed using standard procedures in Escherichia coli strain DH5α (Sambrook ). All PCR reactions were performed using Phusion High-Fidelity DNA Polymerase (New England Biolabs, Beverly, MA). Site-directed mutagenesis was performed with appropriate mismatch oligonucleotide primers using the QuickChange method (Agilent Technologies), according to the manufacturer’s recommendations. The fidelity of all constructs was verified by DNA sequence analysis performed in the University of California Berkeley DNA Sequencing Facility.
Table 2

Plasmids used in this study

PlasmidDescriptionSource or reference
pRS315CEN, LEU2, vectorSikorski and Hieter (1989)
pFR246pRS315 Ypk1(S51A S71A T504A S644A T662A)-mycThis study
pFR249pRS315 Ypk1(S51A T57A S71A T504A S644A T662A)-mycThis study
pFR252pRS315 Ypk1(S51A T57A S71A T504A S644A S653A T662A)-mycMuir et al. (2015)
pFR255pRS315 Ypk1(S51A T57A S63A S64A S71A T504A S644A S653A T662A)-mycThis study
pFR264pRS315 Ypk1(S51A T57A S63A S64A S71A T504A S644A S653A T662A S671A S672A)-mycRoelants et al. (2011)
pJEN9pRS315 Ypk1(S51A T57A S63A S64A S71A T504A S644A S653A T662A S671A S672A S678A)-mycThis study
pKL28pFR264 A671SThis study
pKL29pFR264 A672SThis study
BG18052 µm, URA3, PGAL1, C-terminal tandem affinity (TAP) tag vectorOpen Biosystems/Dharmacon/GE Healthcare
pAX50BG1805 Ypk1(L424A)-TAPMuir et al. (2014)
pAM20pRS315 Ypk1-mycRoelants et al. (2011)
pFR221pRS315 Ypk1(T662A)-mycRoelants et al. (2011)
pFR284pRS315 Ypk1(T662E)-mycThis study
pJEN3pRS315 Ypk1(S653A S671A S672A S678A)-mycThis study
pJEN6pRS315 Ypk1(S653E S671D S672E S678E)-mycThis study
pFR220pRS315 Ypk1(S644A)-mycThis study
pFR253pRS315 Ypk1(S653A)-mycThis study
pFR268pRS315 Ypk1(S671A S672A)-mycThis study
pJEN8pRS315 Ypk1(S678A)-mycThis study
pFR234pRS315 Ypk1(D242A)-mycThis study
pKL7pRS315 Ypk1(D242A T662A)-mycThis study
pJEN4pRS315 Ypk1(D242A S653A S671A S672A S678A)-mycThis study
pPL215p416 pMET25 Ypk1-3HANiles et al. (2012)
pJEN5p416 pMET25 Ypk1(S653A S671A S672A S678A)-3HAThis study
pKL32p416 pMET25 Ypk1(T662A)-3HAThis study
YEp352GALURA3-marked GAL promoter-containing 2 µm vectorBenton et al. (1994)
pFR111YEp352GAL-Ypk1(T504A)-mycRoelants et al. (2010)
pAM76YEp352GAL-Ypk1-mycRoelants et al. (2002)
pFR112Yep352GAL-Ypk1-mycThis study
YEp351LEU2-marked 2 µm vectorHill et al. (1986)
pKL49YEp351 Ypk1 (S653A S671A S672A S678A)-mycThis study

Cell extract preparation and immunoblotting

Samples (1.5 ml) of exponentially growing cells were harvested by brief centrifugation and stored at −80°. Cell pellets were thawed on ice; lysed in 150 µl 1.85 M NaOH, 7.4% β-mercaptoethanol; and proteins in the resulting lysate were precipitated by addition of 150 µl 50% trichloroacetic acid on ice for 10 min. Precipitated proteins were pelleted by centrifugation and washed twice with ice-cold acetone. The pellets were solubilized in a volume of 0.1 M Tris, 5% SDS to yield a final concentration representing an amount of the initial cell culture of A600 nm = 0.025 per µl, and then 5× SDS sample buffer was added to a final concentration of 1×. For samples subjected to phosphatase treatment, the precipitated protein was solubilized in 100 µl solubilization buffer (125 mM sorbitol, 180 mM Tris base, 42 mM NaCl, 10.5 mM MgCl2, 420 µM EDTA, 4% SDS, 2% β-mercaptoethanol), diluted with 900 µl 50 mM Tris-HCl (pH 8.5), and treated with 45 U of calf intestinal alkaline phosphatase (New England Biolabs) at 37° for 2 hr. After treatment, proteins were recollected by trichloroacetic acid precipitation and resuspended in 0.1 M Tris, 5% SDS as described above. Once solubilized, samples to be analyzed by SDS-PAGE were boiled for 10 min. Extracts containing Ypk1-myc were resolved by Phos-tag SDS-PAGE (Kinoshita ) in 8% acrylamide containing 35 µM Phos-tag affinity reagent (Wako Chemicals). To resolve 3XFLAG-Orm1 isoforms, extracts were analyzed by SDS-PAGE using 10% gels containing an acrylamide:bis-acrylamide ratio of 75:1 run at 70 V (Roelants ). Resolved proteins were transferred electrophoretically to a nitrocellulose membrane. The resulting membranes were blocked by incubation in Odyssey buffer (LI-COR) diluted 1:1 with PBS or TBS, then probed by incubation with an appropriate primary antibody (at the indicated dilution): mouse anti-c-myc mAb 9E10 (1:100; Monoclonal Antibody Facility, Cancer Research Laboratory, University of California, Berkeley); mouse anti-FLAG M2 (1:10,000; Sigma-Aldrich); rabbit anti-phospho-Thr662 Ypk1 (1:20,000; gift from Ted Powers, University of California, Davis); mouse anti-HA.11 (1:1000; BioLegend); rabbit polyclonal anti-Avo3 (1:100; this laboratory); goat anti-Tor2 antibodies (1:1000; Santa Cruz Biotechnology, Dallas, TX); and rabbit anti-phospho-Thr256 SGK1 (1:1000; Santa Cruz Biotechnology), which detects the equivalent site (phospho-Thr504) in Ypk1. After washing, filter-bound immune complexes were detected by incubation with an appropriate infrared dye-labeled secondary antibody—CF770-conjugated goat anti-mouse IgG (Biotium), IRDye800CW-conjugated goat anti-rabbit IgG, or IRDye680RD-conjugated goat anti-mouse IgG (Li-Cor) —diluted 1:10,000 in a 1:1 mixture of Odyssey buffer with either PBS or TBS containing 0.1% Tween 20 and 0.02% SDS. After washing, immunoblots were analyzed using an infrared imaging system (Odyssey, LI-COR).

Identification of phosphorylation sites by mass spectrometry

Ypk1 was isolated from yeast extracts by immunoprecipitation; converted to peptide fragments by protease digestion, from which phospho-peptides were enriched by adsorption to Ti(O)2, as described previously (Huber ); and then analyzed by mass spectrometry (MS) on an Orbitrap mass spectrometer (Thermo Fisher Scientific); all by minor modifications of procedures described in detail elsewhere (Breslow ).

Immunoprecipitation of TORC2

A culture (1 L) of yeast cells expressing Avo3-3C-3XFLAG (yNM695) was grown in YPD to midexponential phase and harvested by centrifugation. Cells were washed once in 2× TNEGT buffer [100 mM Tris, pH 7.6, 300 mM NaCl, 20% glycerol, 0.24% Tergitol, 2 mM EDTA, 2 mM NaVO4, 10 mM NaF, 10 mM Na-PPi, 10 mM β-glycerol phosphate, and 1× Roche Complete Protease Inhibitor tablet (Roche, Basel, Switzerland)], then resuspended in 4 ml of 2× TNEGT buffer, and frozen in droplets in liquid nitrogen. The cells were lysed cryogenically using a Mixer Mill MM301 (Retsch, Düsseldorf, Germany). After the lysate was thawed on ice, 8 ml 1× TNEGT buffer [50 mM Tris, pH 7.6, 150 mM NaCl, 10% glycerol, 0.12% Tergitol, 1 mM EDTA, 2 mM NaVO4, 10 mM NaF, 10 mM Na-PPi, 10 mM β-glycerol phosphate, 1× Roche Complete Protease Inhibitor tablet (Roche)] was added and the lysate was clarified by centrifugation at 2000 × g for 15 min. tcgqz complexes, marked by the tightly bound Avo3-3C-3XFLAG subunit, were collected by immunoabsorption to 60 µl of mouse anti-FLAG antibody coupled-agarose resin (Sigma-Aldrich) equilibrated in 1× TNEGT buffer for 2 hr at 4°. The resin was washed four times in 1× TNEGT buffer without protease inhibitors and two times in P3C cleavage buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 0.12% Tergitol, 1 mM DTT, 2 mM NaVO4, 10 mM NaF, 10 mM Na-PPi, 10 mM β-glycerol phosphate). Avo3-3C-3XFLAG-containing TORC2 complexes were eluted by incubation with 12 U PreScission Protease (GE Healthcare, Little Chalfont, United Kingdom) in P3C buffer at 4° for 4 hr.

In vitro kinase assay

Analog-sensitive Ypk1(L424A)-TAP, expressed in yeast cells from a modified version (Dharmacon/GE Healthcare) of the vector BG1805 (Gelperin ) (pAX50), was purified as described previously (Muir ), incubated with either a mock immunoprecipitation or TORC2 complex isolated as described in the preceding section in 1× kinase assay buffer (20 mM Tris-HCl, pH 7.6, 50 mM NaCl, 5 mM MgCl2, 1 mM PMSF, 1 mM DTT, plus 20 μM 3-MB-PP1 to block Ypk1 activity) in either the absence or presence of 250 µM NVP-BEZ235, a demonstrated inhibitor of yeast TORC2 (Kliegman ). Reactions were initiated by the addition of 200 µM ATP containing 5 µCi [γ-32P]ATP (PerkinElmer, Waltham, MA), incubated for 30 min at 30°, and terminated by the addition of 5× SDS-PAGE sample buffer to a 1× final concentration and boiling for 10 min. Reaction products were resolved by SDS-PAGE and analyzed by Coomassie Blue staining and by autoradiography using a Typhoon Imaging System (GE Healthcare).

Data availability

Upon request, we will freely send readily renewable research materials (e.g., plasmids and strains) and reagents (e.g., antibodies, if adequate supplies are available) that were generated during the course of this study to investigators at any and all not-for-profit institutions for research purposes. The authors state that all data necessary for confirming the conclusions presented in the article are represented fully within the article.

Results

Ypk1 is phosphorylated at four previously uncharacterized C-terminal sites

Prior work has documented that Ypk1 is phosphorylated at five sites by three types of protein kinases (Figure 1A). Pkh1 and its paralog Pkh2 phosphorylate Thr504 in the activation loop of the kinase fold (Casamayor ; Roelants ). TORC2 phosphorylates the turn (Ser644) and hydrophobic (Thr662) motifs (Roelants , 2011; Kamada ; Niles ). Fpk1 and its paralog Fpk2 phosphorylate Ser51 and Ser71 (Roelants ) in the N-terminal negative regulatory domain (Roelants ). To obtain additional insight about Ypk1 regulation, we examined whether Ypk1 is phosphorylated at any sites other than the five previously characterized. For this purpose, we expressed an epitope-tagged derivative of a mutant, Ypk1(S51A S71A T504A S644A T662A) (hereafter Ypk15A-myc) lacking the five previously characterized phosphorylation sites. To analyze the species present, we used phosphate-affinity SDS-PAGE (Phos-tag gels), which resolve phosphorylated isoforms (Kinoshita ); the more highly phosphorylated a protein, the slower its mobility. We found that Ypk15A-myc exhibited multiple slower mobility bands, which were due to phosphorylation because they were nearly all removed and collapsed into a single faster mobility species upon phosphatase treatment (Figure 1B). To identify previously uncharacterized phosphorylation sites, we immunopurified native Ypk1 from cells in balanced growth and used MS to analyze the phospho-peptides present. Reassuringly, our MS analysis recovered phosphorylation at four (S71, T504, S644, and T662) of the five previously described sites in Ypk1, but many other apparent sites of phosphorylation were also detected (Figure 1C). As one means to pinpoint which sites of phosphorylation were responsible for generating which observed phospho-isoform, candidate Ser and/or Thr residues were mutated in Ypk15A-myc, alone or in combination, and the resulting effect on the migration pattern analyzed using Phos-tag gels. Although Thr57 and Ser64 were detectably phosphorylated as assessed by our MS analysis, we could observe no effect of a T57A mutation alone or combined with a S64A mutation (along with a neighboring S63A mutation) on the spectrum of species present (Figure 1D). In marked contrast, when three C-terminal residues (Ser653, Ser671, and Ser672) were mutated to Ala, each caused a readily observable loss of a specific isoform (Figure 1D). Although Ser671 was not identified as phosphorylated by MS, further analysis revealed that both Ser671 and Ser672 can be phosphorylated in vivo, as judged by corresponding Phos-tag gel migration shifts (Figure 1E). Because all three of these newly confirmed phosphorylation sites are located quite near the C-terminal end of Ypk1, we tested whether Ser678 was the phosphorylation site responsible for the single remaining isoform observed when all the other sites were removed from Ypk15A-myc (i.e., Ypk111A-myc). Indeed, a S678A mutation (i.e., Ypk112A-myc) eliminated this last slower mobility species (Figure 1D), confirming that Ser678 too can be phosphorylated in vivo.
Figure 1

Ypk1 is phosphorylated at four previously uncharacterized C-terminal sites. (A) Primary structure of Ypk1 depicted schematically. Catalytic domain and N- and C-terminal regulatory elements indicated. Two N-terminal residues phosphorylated by Fpk1 and, less efficiently, by Fpk2 also shown. Shading reflects percent sequence identity between Ypk1 (680 residues) and the corresponding segment in its paralog Ypk2 (677 residues): 1–98, 22% (faint blue); 99–341, 62% (medium blue); 342–602, 90% (black); and, 603–680, 73% (dark blue). AL, activation loop Thr, phosphorylated by Pkh1 and, less efficiently, by Pkh2; HM, hydrophobic motif Thr, phosphorylated by TORC2; TM, turn motif Ser, phosphorylated by TORC2. (B) WT cells (BY4741) expressing Ypk15A-myc from a CEN plasmid (pFR246) were grown to midexponential phase, harvested, lysed, and samples of the resulting extract incubated in the absence or presence of phosphatase. These samples were then resolved by Phos-tag SDS-PAGE and analyzed by immunoblotting with anti-myc mAb 9E10. (C) Ypk1 was isolated from yeast extracts by immunoprecipitation; converted to peptide fragments by protease digestion, from which phospho-peptides were enriched; and then analyzed by MS, as described in Materials and Methods. Sequences recovered, blue underlined; phosphorylation sites, boxed residues; sites mutated in Ypk112A [Ypk1(S51A T57A S63A S64A S71A T504A S644A S653A T662A S671A S672A S678)]; see also rightmost lane in (D)], red; and, new TORC2-dependent phosphorylation sites confirmed by band shift, *. (D) WT cells (BY4741) expressing Ypk15A-myc (pFR246) or derivatives of Ypk15A-myc lacking the additional indicated sites; Ypk16A-myc (pFR249), Ypk17A-myc (pFR252), Ypk19A-myc (pFR255), Ypk111A-myc (pFR264), or Ypk112A-myc (pJEN9); were examined as in (B) without any phosphatase treatment. (E) WT cells (BY4741) expressing Ypk111A-myc (pFR264) or derivatives of Ypk111A-myc in which the indicated additional phosphorylation site was restored, Ypk111A 671S-myc (pKL28) or Ypk111A 672S-myc (pKL29), were examined as in (D). IB, immunoblot. In (D) and (E), red arrows indicate the change in the migration pattern caused by the indicated mutation(s).

Ypk1 is phosphorylated at four previously uncharacterized C-terminal sites. (A) Primary structure of Ypk1 depicted schematically. Catalytic domain and N- and C-terminal regulatory elements indicated. Two N-terminal residues phosphorylated by Fpk1 and, less efficiently, by Fpk2 also shown. Shading reflects percent sequence identity between Ypk1 (680 residues) and the corresponding segment in its paralog Ypk2 (677 residues): 1–98, 22% (faint blue); 99–341, 62% (medium blue); 342–602, 90% (black); and, 603–680, 73% (dark blue). AL, activation loop Thr, phosphorylated by Pkh1 and, less efficiently, by Pkh2; HM, hydrophobic motif Thr, phosphorylated by TORC2; TM, turn motif Ser, phosphorylated by TORC2. (B) WT cells (BY4741) expressing Ypk15A-myc from a CEN plasmid (pFR246) were grown to midexponential phase, harvested, lysed, and samples of the resulting extract incubated in the absence or presence of phosphatase. These samples were then resolved by Phos-tag SDS-PAGE and analyzed by immunoblotting with anti-myc mAb 9E10. (C) Ypk1 was isolated from yeast extracts by immunoprecipitation; converted to peptide fragments by protease digestion, from which phospho-peptides were enriched; and then analyzed by MS, as described in Materials and Methods. Sequences recovered, blue underlined; phosphorylation sites, boxed residues; sites mutated in Ypk112A [Ypk1(S51A T57A S63A S64A S71A T504A S644A S653A T662A S671A S672A S678)]; see also rightmost lane in (D)], red; and, new TORC2-dependent phosphorylation sites confirmed by band shift, *. (D) WT cells (BY4741) expressing Ypk15A-myc (pFR246) or derivatives of Ypk15A-myc lacking the additional indicated sites; Ypk16A-myc (pFR249), Ypk17A-myc (pFR252), Ypk19A-myc (pFR255), Ypk111A-myc (pFR264), or Ypk112A-myc (pJEN9); were examined as in (B) without any phosphatase treatment. (E) WT cells (BY4741) expressing Ypk111A-myc (pFR264) or derivatives of Ypk111A-myc in which the indicated additional phosphorylation site was restored, Ypk111A 671S-myc (pKL28) or Ypk111A 672S-myc (pKL29), were examined as in (D). IB, immunoblot. In (D) and (E), red arrows indicate the change in the migration pattern caused by the indicated mutation(s). As a first means to ascertain the potential biological significance of these newly identified phosphorylation sites, we aligned the amino acid sequences of the C-terminal end of S. cerevisiae Ypk1 with the corresponding sequence in its paralog Ypk2 and in their homologs from five sensu stricto Saccharomyces species, from 10 other yeast species, and from human SGK1. Not unexpectedly, we found complete conservation of the residues equivalent to the turn (S644 in Ypk1) and hydrophobic (T662 in Ypk1) motifs in all 18 proteins (Figure 2). Strikingly, however, we also found complete conservation of a phosphorylatable residue at three of the newly identified phosphorylation sites (S653, S672, and S678 in Ypk1) (Figure 2). Notably, even the sequence context surrounding these residues was also rather well conserved. Even though the most distant relatives, e.g., Schizosaccharomyces pombe Gad8 and human SGK1, share only modest overall homology in this region with S. cerevisiae Ypk1, their C termini still contain putative phosphorylation sites at positions equivalent to three of those we identified. By contrast, in SGK1, Gad8, and three other yeast species, no residue equivalent to S671 in Ypk1 is present.
Figure 2

Sequence comparison of the C-terminal ends of Ypk1 homologs. The amino acid sequence of the C-terminal end of S. cerevisiae (Sce) Ypk1 (top line) was aligned with the corresponding segment of Ypk1 orthologs from the sensu stricto group S. paradoxus (Spa), S. kudriavzevii (Sku), S. mikatae (Smi), S. arboricola (Sar), S. bayanus (Sba), the more divergent species Vanderwaltozyma polyspora (Vpo), Zygosaccharomyces rouxii (Zro), Candida glabrata (Cgl), S. castellii (Sca), S. kluyveri (Skl), Ashbya gossypii (Ago), Kluveromyces waltii (Kwa), Lachancea thermotolerans (Lth), K. lactis (Kla), S. pombe (Spo), its S. cerevisiae paralog Ypk2, and its human (Hs) counterpart SGK1 (bottom line). To emphasize the degree of relatedness to S. cerevisiae Ypk1, only identities between the other proteins and S. cerevisiae Ypk1 are indicated (white letters on black boxes). One-residue gaps (–) and insertions of the indicated length (parentheses) were introduced to maximize the alignment of the most distant orthologs. Period (.) indicates the end of the ORF. Matches to our consensus TORC2 phospho-acceptor site motif (-S/T-Hpo-, where Hpo denotes any hydrophobic residue) (yellow boxes with phosphorylation site in bold red and hydrophobic residue in bold black). The two classical sites for TORC2-mediated phosphorylation—the so-called turn motif (TM) and hydrophobic motif (HM) (Pearce )—and the additional sites (NEW) discovered in this study are indicated above, along with the corresponding residue in S. cerevisiae Ypk1. Sequence sources were: Sce (strain S288C) from the Saccharomyces Genome Database (http://www.yeastgenome.org/locus/S000001609/protein); Spa, Sku, Smi, Sba, Sca, and Skl (Cliften ; Kellis ); Sar (GenBank EJS42953.1), Vpo (GenBank EDO19622.1), Zro (EMBL Bank CAR29179.1), and Lth (EMBL Bank CAR22493.1); Cgl, Ago, Kwa, Kla, Spo, and Sce Ypk2 from the Fungal Orthogroups database at the Broad Institute (https://portals.broadinstitute.org/cgi-bin/regev/orthogroups/show_orthogroup.cgi?orf=YKL126W); and Hs SGK1, isoform 2 (GenBank ACD35864.1).

Sequence comparison of the C-terminal ends of Ypk1 homologs. The amino acid sequence of the C-terminal end of S. cerevisiae (Sce) Ypk1 (top line) was aligned with the corresponding segment of Ypk1 orthologs from the sensu stricto group S. paradoxus (Spa), S. kudriavzevii (Sku), S. mikatae (Smi), S. arboricola (Sar), S. bayanus (Sba), the more divergent species Vanderwaltozyma polyspora (Vpo), Zygosaccharomyces rouxii (Zro), Candida glabrata (Cgl), S. castellii (Sca), S. kluyveri (Skl), Ashbya gossypii (Ago), Kluveromyces waltii (Kwa), Lachancea thermotolerans (Lth), K. lactis (Kla), S. pombe (Spo), its S. cerevisiae paralog Ypk2, and its human (Hs) counterpart SGK1 (bottom line). To emphasize the degree of relatedness to S. cerevisiae Ypk1, only identities between the other proteins and S. cerevisiae Ypk1 are indicated (white letters on black boxes). One-residue gaps (–) and insertions of the indicated length (parentheses) were introduced to maximize the alignment of the most distant orthologs. Period (.) indicates the end of the ORF. Matches to our consensus TORC2 phospho-acceptor site motif (-S/T-Hpo-, where Hpo denotes any hydrophobic residue) (yellow boxes with phosphorylation site in bold red and hydrophobic residue in bold black). The two classical sites for TORC2-mediated phosphorylation—the so-called turn motif (TM) and hydrophobic motif (HM) (Pearce )—and the additional sites (NEW) discovered in this study are indicated above, along with the corresponding residue in S. cerevisiae Ypk1. Sequence sources were: Sce (strain S288C) from the Saccharomyces Genome Database (http://www.yeastgenome.org/locus/S000001609/protein); Spa, Sku, Smi, Sba, Sca, and Skl (Cliften ; Kellis ); Sar (GenBank EJS42953.1), Vpo (GenBank EDO19622.1), Zro (EMBL Bank CAR29179.1), and Lth (EMBL Bank CAR22493.1); Cgl, Ago, Kwa, Kla, Spo, and Sce Ypk2 from the Fungal Orthogroups database at the Broad Institute (https://portals.broadinstitute.org/cgi-bin/regev/orthogroups/show_orthogroup.cgi?orf=YKL126W); and Hs SGK1, isoform 2 (GenBank ACD35864.1).

TORC2 is responsible for phosphorylating Ypk1 at the newly identified C-terminal sites

As an initial approach to determine which protein kinase(s) is responsible for phosphorylating Ypk1 at the new C-terminal sites, we expressed Ypk15A-myc in a targeted collection of derivatives of the yeast strain BY4741 or BY4742 that either lack the ORF (for nonessential genes) or bear a temperature-sensitive mutation (for essential genes) for 113 of the 127 protein kinases encoded in the yeast genome (Rubenstein and Schmidt 2007; Mok ). We then examined the phospho-isoforms present in extracts of these cells using Phos-tag gels. Strikingly, the only mutation of a Ser/Thr protein kinase that affected phosphorylation of Ypk15A-myc was a allele; even at permissive temperature, Ypk15A-myc phosphorylation was markedly reduced and, after shift to the restrictive temperature, it was eliminated completely (Figure 3A). Thus, Tor2 activity is required for phosphorylation of Ypk1 at the new sites. However, Tor2 can function in either TORC1 or TORC2 (Kunz ; Helliwell ; Loewith ; Wedaman ). Hence, we examined Ypk15A-myc phosphorylation in a strain (∆) (Gaubitz ) in which TORC1 is resistant and TORC2 is susceptible to inhibition by rapamycin. We found that in the absence of rapamycin the majority of Ypk15A-myc migrated as phosphorylated (slower mobility) isoforms, whereas after treatment with rapamycin, the bulk of the Ypk15A-myc migrated as the unphosphorylated species (Figure 3B, left); indicating that, just as previously found for the turn and hydrophobic motifs, TORC2 activity is required for phosphorylation of Ypk1 at the new C-terminal sites. As an additional control, we found, in separate experiments, that Ypk15A-myc expressed in wild-type (WT) cells exhibited no change in migration pattern when treated with rapamycin (Figure 3B, right). Even though Ypk15A-myc itself is inactive (because it cannot be phosphorylated at either the activation loop or the turn and hydrophobic motifs), perhaps autophosphorylation in trans by endogenous Ypk1 or Ypk2 could contribute to the observed phosphorylation at the new C-terminal sites. However, we ruled out this possibility because Ypk15A-myc showed no change in migration pattern when expressed in ∆ cells, regardless of whether or not they were treated with the Ypk1as inhibitor (3-MB-PP1) (Figure 3C).
Figure 3

TORC2 phosphorylates the novel C-terminal sites. (A) WT (BY4741) or otherwise isogenic tor2 cells expressing Ypk15A-myc (pFR246) were grown at 26° to midexponential phase and then either kept at 26° or shifted to 37° for 2 hr, harvested, lysed, and samples of the resulting extracts resolved by Phos-tag SDS-PAGE and analyzed by immunoblotting with anti-myc mAb 9E10. (B) TOR1-1 avo3∆ cells (left) expressing Ypk15A-myc (pFR246) were grown to midexponential phase, treated for 20 min with either vehicle alone (Tween 20:ethanol, 10:90) or 200 nM rapamycin in the same solvent as indicated, collected, and analyzed as in (A). WT cells (BY4741) expressing Ypk15A-myc (pFR246) (right) were treated in the same manner in a separate experiment. (C) Strain yAM135-A (ypk1∆) expressing Ypk15A-myc (pFR246) was grown to midexponential phase and then treated with either vehicle alone (DMSO) or 10 µM 3-MB-PP1 for 1 hr, harvested, and then analyzed as in (A). (D) WT (Mock IP) (yKL4) and Avo3-3C-3XFLAG (TORC2 IP) (yNM695) strains were grown in YPD to midexponential phase, harvested, lysed, and TORC2 immunoprecipitated from the resulting extracts using anti-FLAG antibody-coupled agarose resin. Immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by immunoblotting with anti-Avo3 and anti-Tor2 antibodies. (E) Mock and TORC2 preparations, as in (D), were incubated with [γ-32P]ATP, either alone or in the presence of purified analog-sensitive Ypk1as, in either the absence or presence of the TORC2 inhibitor NVP-BEZ235, as indicated. Reaction products were resolved by SDS-PAGE and analyzed by Coomassie staining and, after drying the gel, by autoradiography.

TORC2 phosphorylates the novel C-terminal sites. (A) WT (BY4741) or otherwise isogenic tor2 cells expressing Ypk15A-myc (pFR246) were grown at 26° to midexponential phase and then either kept at 26° or shifted to 37° for 2 hr, harvested, lysed, and samples of the resulting extracts resolved by Phos-tag SDS-PAGE and analyzed by immunoblotting with anti-myc mAb 9E10. (B) TOR1-1 avo3∆ cells (left) expressing Ypk15A-myc (pFR246) were grown to midexponential phase, treated for 20 min with either vehicle alone (Tween 20:ethanol, 10:90) or 200 nM rapamycin in the same solvent as indicated, collected, and analyzed as in (A). WT cells (BY4741) expressing Ypk15A-myc (pFR246) (right) were treated in the same manner in a separate experiment. (C) Strain yAM135-A (ypk1∆) expressing Ypk15A-myc (pFR246) was grown to midexponential phase and then treated with either vehicle alone (DMSO) or 10 µM 3-MB-PP1 for 1 hr, harvested, and then analyzed as in (A). (D) WT (Mock IP) (yKL4) and Avo3-3C-3XFLAG (TORC2 IP) (yNM695) strains were grown in YPD to midexponential phase, harvested, lysed, and TORC2 immunoprecipitated from the resulting extracts using anti-FLAG antibody-coupled agarose resin. Immunoprecipitated proteins were resolved by SDS-PAGE and analyzed by immunoblotting with anti-Avo3 and anti-Tor2 antibodies. (E) Mock and TORC2 preparations, as in (D), were incubated with [γ-32P]ATP, either alone or in the presence of purified analog-sensitive Ypk1as, in either the absence or presence of the TORC2 inhibitor NVP-BEZ235, as indicated. Reaction products were resolved by SDS-PAGE and analyzed by Coomassie staining and, after drying the gel, by autoradiography. Finally, to confirm, as also reported by others (Niles ), that Ypk1 is a direct substrate of TORC2 in vitro, we purified TORC2 complexes by immuno-isolation (Figure 3D). When incubated alone, we observed robust autophosphorylation of TORC2 constituents (Figure 3E). When incubated in the presence of purified Ypk1as (in the presence of 3-MB-PP1 to block its activity), we observed robust phosphorylation of Ypk1as, as well as a corresponding reduction in TORC2 autophosphorylation, as expected for inhibition of autophosphorylation by the presence of a bona fide competing substrate (Figure 3E). Moreover, when the TORC2 inhibitor NVP-BEZ235 was added, incorporation into Ypk1 and TORC2 autophosphorylation were both greatly diminished. Thus, as expected, Ypk1 is a direct TORC2 substrate. To confirm that the observed TORC2-dependent incorporation occurred not only at S644 and T662, but also at the additional C-terminal sites in Ypk1, we attempted to purify a Ypk1as(S653A S671A S672A S678A) mutant. However, as discussed in greater detail below, these mutations greatly destabilized Ypk1, making recovery of sufficient purified protein technically problematic.

Phosphorylation at the new C-terminal sites is necessary for optimal Ypk1 function

The antibiotic myriocin (Myr), also known as ISP-1 (Miyake ; Ikushiro ; Yeung 2011), inhibits eukaryotic cell growth because it is a transition-state mimic that potently blocks L-serine:palmitoyl-CoA C-palmitoyltransferase (decarboxylating) (EC 2.3.1.50), the first enzyme unique to the sphingolipid biosynthetic pathway (Dunn ; Dickson ; Megyeri ; Olson ). Moreover, prior work has demonstrated that Ypk1-deficient cells are hypersensitive to the growth-inhibitory action of Myr (Momoi ; Roelants ). Subsequent studies revealed that TORC2-stimulated, Ypk1-mediated phosphorylation of several substrates that are rate limiting for sphingolipid production is required for cell survival in response to sphingolipid limitation (Roelants ; Berchtold ; Muir ). Hence, the degree of resistance to Myr provides a convenient phenotypic read out for the efficacy of Ypk1 function in vivo. Therefore, to assess whether TORC2-dependent phosphorylation of Ypk1 at its C-terminal sites modulates Ypk1 function, we tested the Myr sensitivity of various unphosphorylatable and phospho-mimetic alleles of Ypk1 in ∆ cells. As expected, a Ypk1T662A-myc mutant (Figure 4A), which cannot be phosphorylated by TORC2 at the hydrophobic motif, and a Ypk1S644A-myc mutant, which cannot be phosphorylated by TORC2 at the turn motif (Figure 4B), displayed much greater sensitivity to Myr than cells expressing Ypk1WT-myc (Figure 4A). Similarly, a mutant lacking all four of the newly identified C-terminal phosphorylation sites [Ypk1(S653A S671A S672A S678A)-myc, hereafter Ypk1AAAA-myc] exhibited increased Myr sensitivity, but at a somewhat higher concentration of this compound (Figure 4A), whereas loss of one or even two of these sites exhibited no noticeable increase in Myr sensitivity (Figure 4B), suggesting that the effects of phosphorylation at these positions may be additive in stimulating Ypk1 action. Indeed, in marked contrast to the Myr sensitivity of cells expressing Ypk1AAAA-myc, a mutant in which the same four residues were mutated to Glu or Asp (Ypk1EDEE-myc) supported robust growth in the presence of Myr, indicating that mimicking phosphorylation at these four sites allows for full Ypk1 function (Figure 4A).
Figure 4

TORC2-dependent phosphorylation of Ypk1 at the new C-terminal sites is required for full Ypk1 function. (A) Cultures of ypk1∆ cells containing either empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1T662A-myc (pFR221), Ypk1T662E-myc (pFR284), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1S653E S671D S672E S678E-myc (pJEN6) were adjusted such that A600 nm = 1.0 and then spotted in 10-fold serial dilutions onto SCD-Leu plates containing the indicated concentrations of Myr and incubated at 30° for 3 days. (B) Serial dilutions of ypk1∆ cells containing either empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1S644A-myc (pFR220), Ypk1T662A-myc (pFR221), Ypk1S653A-myc (pFR253), Ypk1S671A S672A-myc (pFR268), or Ypk1S678A-myc (pJEN8) were analyzed as in (A). (C) Cultures of ypk1∆ cells containing either empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1D242A-myc (pFR234), Ypk1T662A-myc (pFR221), Ypk1D242A T662A-myc (pKL7), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1D242A 653A S671A S672A S678A-myc (pJEN4) were analyzed as in (A). (D) Strain yDB344 (3XFLAG-ORM1 ypk1∆) expressing either Ypk1WT-myc (pAM20), Ypk1S653A S671A S672A S678A-myc (pJEN3), Ypk1D242A S653A S671A S672A S678A-myc (pJEN4), Ypk1S653E S671D S672E S672E-myc (pJEN6), or Ypk1D242A-myc (pFR234) were grown to exponential phase in selective medium, treated with either vehicle (methanol) or 1.25 µM Myr for 2 hr. After harvesting, whole-cell extracts were prepared, resolved by SDS-PAGE, and analyzed by immunoblotting with anti-FLAG M2 antibody.

TORC2-dependent phosphorylation of Ypk1 at the new C-terminal sites is required for full Ypk1 function. (A) Cultures of ypk1∆ cells containing either empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1T662A-myc (pFR221), Ypk1T662E-myc (pFR284), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1S653E S671D S672E S678E-myc (pJEN6) were adjusted such that A600 nm = 1.0 and then spotted in 10-fold serial dilutions onto SCD-Leu plates containing the indicated concentrations of Myr and incubated at 30° for 3 days. (B) Serial dilutions of ypk1∆ cells containing either empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1S644A-myc (pFR220), Ypk1T662A-myc (pFR221), Ypk1S653A-myc (pFR253), Ypk1S671A S672A-myc (pFR268), or Ypk1S678A-myc (pJEN8) were analyzed as in (A). (C) Cultures of ypk1∆ cells containing either empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1D242A-myc (pFR234), Ypk1T662A-myc (pFR221), Ypk1D242A T662A-myc (pKL7), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1D242A 653A S671A S672A S678A-myc (pJEN4) were analyzed as in (A). (D) Strain yDB344 (3XFLAG-ORM1 ypk1∆) expressing either Ypk1WT-myc (pAM20), Ypk1S653A S671A S672A S678A-myc (pJEN3), Ypk1D242A S653A S671A S672A S678A-myc (pJEN4), Ypk1S653E S671D S672E S672E-myc (pJEN6), or Ypk1D242A-myc (pFR234) were grown to exponential phase in selective medium, treated with either vehicle (methanol) or 1.25 µM Myr for 2 hr. After harvesting, whole-cell extracts were prepared, resolved by SDS-PAGE, and analyzed by immunoblotting with anti-FLAG M2 antibody. It has been shown previously that the N-terminal mutation D242A bypasses the need for TORC2-mediated phosphorylation of Ypk1 (Roelants ), suggesting that the N-terminal domain exerts some negative regulatory constraint on the C-terminal catalytic domain, in agreement with prior evidence (Roelants ). Thus, it seems that the role of TORC2-mediated phosphorylation, like the D242A mutation, is to alleviate the inhibitory constraint imposed by the N-terminal domain. Consistent with that model, installing the D242A mutation in either Ypk1T662A-myc or Ypk1AAAA-myc fully restored their ability to support growth in the presence of Myr (Figure 4C). To assess the effect of TORC2-dependent phosphorylation at the newly defined C-terminal sites on Ypk1 activity, we examined its ability to phosphorylate a known substrate in vivo. We have shown previously that Myr treatment stimulates Ypk1-mediated phosphorylation of Orm1 and that mutating a critical TORC2 target site in Ypk1 (T662) substantially reduces the ability of Ypk1 to phosphorylate Orm1 after Myr treatment (Roelants ). Therefore, we monitored Ypk1-dependent phosphorylation of Orm1 after Myr treatment in cells expressing WT Ypk1 and various Ypk1 mutants. Cells expressing Ypk1AAAA-myc exhibited a marked reduction in Orm1 phosphorylation in response to Myr treatment compared to cells expressing Ypk1WT-myc, whereas cells expressing either Ypk1D242A + AAAA or Ypk1EDEE-myc exhibited a level of Orm1 phosphorylation equivalent to that of WT Ypk1-myc or Ypk1D242A-myc cells (Figure 4D). Collectively, these observations suggested that lack of TORC2 phosphorylation of Ypk1 at the four newly discovered sites significantly compromises Ypk1 function.

Phosphorylation at the new C-terminal sites is also necessary for Ypk1 stability

In addition to modulation of catalytic activity, phosphorylation can change protein stability or localization, which may also influence enzyme function. For this reason, we also examined whether phosphorylation of Ypk1 at the four new C-terminal sites affected its expression level by analyzing the steady-state amount of various Ypk1 unphosphorylatable and phospho-mimetic mutants by immunoblotting (Figure 5A). When extracts from untreated cells were examined by standard SDS-PAGE, Ypk1-myc migrated as a doublet; the slower mobility species represents Ypk1 isoforms phosphorylated by Fpk1 (and Fpk2), and Fpk1 and Fpk2 are themselves phosphorylated and inhibited by Ypk1 (Roelants ). Thus, when cells are treated with Myr and Ypk1 activity is stimulated, Ypk1-dependent phosphorylation of Fpk1/Fpk2 increases, resulting in reduced Fpk-mediated phosphorylation of Ypk1. Hence, in cells treated with Myr, Ypk1-myc ran predominantly as the faster mobility species (and appeared more abundant because the signal is not as diffuse), whereas Ypk1T662A-myc which prevents robust TORC2 activation of Ypk1 did not undergo this shift, but the phospho-mimetic allele Ypk1T662E-myc did (Figure 5A). Moreover, as reported by others (Tanoue ), mutation of the hydrophobic motif phosphorylation site (T662) did not compromise the stability of Ypk1. Strikingly, however, the level of Ypk1AAAA-myc was significantly lower than that of Ypk1WT-myc, Ypk1T662A-myc, or Ypk1T662E-myc and its pattern did not change upon Myr treatment, suggesting that TORC2-dependent phosphorylation at the four new C-terminal sites is important for both Ypk1 stability and function. Consistent with this hypothesis, under the same conditions, the level of the phospho-mimetic mutant Ypk1EDEE-myc was even higher than that of Ypk1WT-myc. These results indicate that the effect on Ypk1 stability is specific to the four new C-terminal sites.
Figure 5

Phosphorylation at the new C-terminal sites promotes Ypk1 stability. (A) Cultures of ypk1∆ cells containing empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1T662A-myc (pFR221), Ypk1T662E-myc (pFR284), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1S653E S671D S672E S678E-myc (pJEN6) were grown to midexponential phase and then treated with vehicle (methanol) or 1.25 µM Myr for 2 hr. After harvesting, whole-cell lysates were prepared, resolved by SDS-PAGE, and analyzed by immunoblotting with anti-myc mAb 9E10. (B) Cultures of ypk1∆ cells containing empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1D242A-myc (pFR234), Ypk1T662A-myc (pFR221), Ypk1D242A T662A-myc (pKL7), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1D242A S653A S671A S672A S678A-myc (pJEN4) were treated and analyzed as in (A). (C) Cultures of ypk1∆ cells expressing from a CEN plasmid either Ypk1WT-myc (pAM20), Ypk1T662A-myc (pFR221), or Ypk1S653A S671A S672A S678A-myc (pJEN3), or expressing from a 2 µm DNA plasmid Ypk1S653A S671A S672A S678A-myc (pKL49), as indicated, were grown to midexponential phase, harvested, and analyzed as in (A). (D) Cultures of ypk1∆ cells containing empty vector (EV) (pRS315), a CEN plasmid expressing Ypk1WT-myc (pAM20), a 2 µm DNA plasmid expressing Ypk1S653A S671A S672A S678A-myc (pKL49), or a CEN plasmid expressing Ypk1T662A-myc (pFR221) were adjusted to a cell density of A600 nm = 1.0 and then spotted in 10-fold serial dilutions onto SCD-Leu agar plates containing vehicle (methanol) or the indicated concentration of Myr. Plates were then incubated at 30° for 2 days prior to imaging. IB, immunoblot.

Phosphorylation at the new C-terminal sites promotes Ypk1 stability. (A) Cultures of ypk1∆ cells containing empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1T662A-myc (pFR221), Ypk1T662E-myc (pFR284), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1S653E S671D S672E S678E-myc (pJEN6) were grown to midexponential phase and then treated with vehicle (methanol) or 1.25 µM Myr for 2 hr. After harvesting, whole-cell lysates were prepared, resolved by SDS-PAGE, and analyzed by immunoblotting with anti-myc mAb 9E10. (B) Cultures of ypk1∆ cells containing empty vector (pRS315) or the same plasmid expressing Ypk1WT-myc (pAM20), Ypk1D242A-myc (pFR234), Ypk1T662A-myc (pFR221), Ypk1D242A T662A-myc (pKL7), Ypk1S653A S671A S672A S678A-myc (pJEN3), or Ypk1D242A S653A S671A S672A S678A-myc (pJEN4) were treated and analyzed as in (A). (C) Cultures of ypk1∆ cells expressing from a CEN plasmid either Ypk1WT-myc (pAM20), Ypk1T662A-myc (pFR221), or Ypk1S653A S671A S672A S678A-myc (pJEN3), or expressing from a 2 µm DNA plasmid Ypk1S653A S671A S672A S678A-myc (pKL49), as indicated, were grown to midexponential phase, harvested, and analyzed as in (A). (D) Cultures of ypk1∆ cells containing empty vector (EV) (pRS315), a CEN plasmid expressing Ypk1WT-myc (pAM20), a 2 µm DNA plasmid expressing Ypk1S653A S671A S672A S678A-myc (pKL49), or a CEN plasmid expressing Ypk1T662A-myc (pFR221) were adjusted to a cell density of A600 nm = 1.0 and then spotted in 10-fold serial dilutions onto SCD-Leu agar plates containing vehicle (methanol) or the indicated concentration of Myr. Plates were then incubated at 30° for 2 days prior to imaging. IB, immunoblot. Although these observations show that phosphorylation at the four new C-terminal sites is important for Ypk1 stability, two further observations demonstrate that the deficit in function of Ypk1AAAA cannot be attributed to its lower level of expression. First, installation of the D242A mutation which fully restored function to Ypk1AAAA-myc, as judged by both Myr resistance (Figure 4A) and efficiency of Orm1 phosphorylation (Figure 4D), did not increase the level of the protein (Figure 5B). In fact, the D242A mutation seemed to destabilize Ypk1WT-myc and especially Ypk1T662-myc to some degree (Figure 5B). Conversely, even when produced at an elevated level by expression from a multi-copy 2 μm DNA plasmid in an amount equivalent to WT Ypk1 (Figure 5C), Ypk1AAAA was still unable to restore Myr resistance (Figure 5D). Hence, the physiological phenotypes associated with loss of phosphorylation at the new C-terminal sites arise largely from impairment of the functional activity of Ypk1.

Phosphorylation at the new C-terminal sites promotes efficient hydrophobic motif phosphorylation

Compared to absence of phosphorylation at the four newly identified C-terminal sites, absence of phosphorylation at either its turn (S644) or its hydrophobic (T662) motif is more crippling to Ypk1 function (Figure 4, A and B). Moreover, despite its much lower steady-state level compared to Ypk1WT-myc (Figure 5B), Ypk1D242A + AAAA-myc exhibited no deleterious phenotypes (Figure 4C). Therefore, we considered the possibility that, at the mechanistic level, the primary role of TORC2-mediated phosphorylation at the four new C-terminal sites is to prime Ypk1 for full activation because modification of these sites helps expose, makes more efficient, or allows for more sustained TORC2-dependent phosphorylation at the turn and hydrophobic motifs. However, for Ypk1 to be active at all, it must also be phosphorylated at Thr504 in its activation loop by Pkh1 (and Pkh2) (Casamayor ; Roelants , 2004). To examine which of these sites of phosphorylation might be compromised when Ypk1 cannot be phosphorylated at the four new C-terminal sites, we used phospho-site-directed antibodies that detect specifically the Pkh1 site (P-Thr504) and the TORC2 site in the hydrophobic motif (P-Thr662). We have demonstrated before that a commercial phospho-site antibody directed against the highly homologous PDK1 site in human SGK1 robustly and specifically detects P-Thr504 in Ypk1 (Roelants ). A phospho-site antibody that specifically detects P-Thr662 in Ypk1 was generated and validated by Powers and co-workers (Niles ), and generously provided to us. To permit proper comparison of the level of phosphorylation in each Ypk1 variant, the volumes of extract loaded were adjusted to ensure that the total amount of Ypk1 present in each lane was equivalent. We found that, compared to Ypk1WT-3HA, phosphorylation of Thr662 is abolished in Ypk1AAAA-3HA down to the background level observed for a Ypk1T662A-3HA mutant which totally lacks the site (Figure 6A); whereas the level of phosphorylation of Thr504 in a Ypk1S644A T662A-myc mutant which lacks the TORC2 sites in both the turn and hydrophobic motifs was unaffected, i.e., comparable to that in Ypk1WT-3HA (Figure 6B). These results show, first, that the modifications at Thr504 and Thr662 occur independently of each other. Second, and more importantly, these findings indicate that the multiple TORC2-mediated modifications at the C-terminal sites (namely at Ser653, Ser671, Ser672, and Ser678) are a prelude to and prerequisite for efficient TORC2-dependent modification of Thr662 (and, presumably, Ser644).
Figure 6

Phosphorylation of the new C-terminal sites is necessary for efficient hydrophobic motif phosphorylation. (A) Cultures of ypk1∆ cells containing plasmids expressing Ypk1-3HA (pPL215), Ypk1S653A S671A S672A S678A-3HA (pJEN5), or Ypk1T662A-3HA (pKL32) were grown to midexponential phase in SCD-Ura then treated with either vehicle (methanol) or 1.25 µM Myr for 2 hr, as indicated. After harvesting, whole-cell extracts were prepared, resolved by SDS-PAGE, and analyzed by immunoblotting with anti-HA and anti-phosphoT662 Ypk1 antibodies. The volume of extract loaded in each lane was adjusted to ensure that the total amount of each Ypk1 variant was equivalent. (B) Strain BY4741 (YPK1) containing plasmids expressing from the GAL promoter Ypk1T504A-myc (pFR111), Ypk1WT-myc (pAM76), or Ypk1S644A T662A-myc (pFR112) were treated with vehicle (methanol) or 1.25 µM Myr for 2 hr and then analyzed by SDS-PAGE and immunoblotting as in (A), except that the antibodies used were anti-myc mAb 9E10 and anti-phospho-Thr256 SGK1 antibodies.

Phosphorylation of the new C-terminal sites is necessary for efficient hydrophobic motif phosphorylation. (A) Cultures of ypk1∆ cells containing plasmids expressing Ypk1-3HA (pPL215), Ypk1S653A S671A S672A S678A-3HA (pJEN5), or Ypk1T662A-3HA (pKL32) were grown to midexponential phase in SCD-Ura then treated with either vehicle (methanol) or 1.25 µM Myr for 2 hr, as indicated. After harvesting, whole-cell extracts were prepared, resolved by SDS-PAGE, and analyzed by immunoblotting with anti-HA and anti-phosphoT662 Ypk1 antibodies. The volume of extract loaded in each lane was adjusted to ensure that the total amount of each Ypk1 variant was equivalent. (B) Strain BY4741 (YPK1) containing plasmids expressing from the GAL promoter Ypk1T504A-myc (pFR111), Ypk1WT-myc (pAM76), or Ypk1S644A T662A-myc (pFR112) were treated with vehicle (methanol) or 1.25 µM Myr for 2 hr and then analyzed by SDS-PAGE and immunoblotting as in (A), except that the antibodies used were anti-myc mAb 9E10 and anti-phospho-Thr256 SGK1 antibodies.

Discussion

Like all eukaryotic protein kinases, members of the AGC subfamily of these enzymes share a common catalytic domain structure consisting of a small N-terminal lobe (N-lobe) and larger C-terminal lobe (C-lobe) with the active site sandwiched between the N-lobe and C-lobe (Pearce ). In AGC-family kinases, phosphorylation at several conserved sites is necessary for their catalytic function. A conserved site essential for activity resides in the activation loop, which is situated nearby the ATP-binding site in the kinase domain. The activation loop, when phosphorylated, makes vital contacts with the catalytic loop and the αC helix; the cumulative conformational changes so induced are essential for opening up the active site cleft, for positioning the catalytic Asp in the proper location, and for enhancing contacts with ATP in its binding pocket, all of which are necessary for catalytic activity (Yang ; Komander ). A second conserved phosphorylation site is the hydrophobic motif near the C terminus. In the structure of mammalian AKT/PKB, the C-terminal sequence extends from the C-lobe, wraps around the N-lobe, and fits into a hydrophobic groove comprised, in part, by the αC helix (Yang ,b). When phosphorylated, the hydrophobic motif appears to stabilize the αC helix in the conformation found in the active state of AKT (Yang ,b). AKT and other AGC-family protein kinases (e.g., S6K, RSK, MSK, PRK, and PKCs) have a third conserved site, known as the turn motif, located in the C-terminal tail upstream of the hydrophobic motif. When phosphorylated, the turn motif interacts with a positively charged pocket in the N-lobe and further stabilizes wrapping of the C-terminal tail around the N-lobe (Grodsky ; Hauge ). Thus, phosphorylations at the hydrophobic motif and turn motif buttress the active state of an AGC kinase and are necessary for its full activation. On the basis of both sequence homology and organization, Ypk1 is clearly a member of the AGC family of protein kinases (Casamayor ; Roelants ). Moreover, Ypk1 is known to require phosphorylation at its activation loop (Thr504) and to be regulated by phosphorylation at its hydrophobic motif (Thr662). Phosphorylation at Thr504 in the activation loop catalyzed by Pkh1 (and Pkh2), which is essential for basal Ypk1 activity (Roelants ), does not change in response to the stress of sphingolipid depletion (Roelants ), but purportedly increases in response to heat stress (Omnus ). TORC2 mediates hydrophobic motif phosphorylation (Roelants ), which is markedly stimulated by sphingolipid depletion (Roelants ; Berchtold ), hypotonic conditions (Berchtold ), heat shock (Sun ), and acetic acid stress (Guerreiro ). As we have confirmed here, the turn motif in Ypk1 (Roelants ) is also essential for Ypk1 function. Moreover, as documented here, we discovered that TORC2 also phosphorylates four other C-terminal sites in Ypk1 (Ser653, Ser671, Ser672, and Ser678) that lie in close propinquity to the turn and hydrophobic motifs. Although we demonstrated that purified Ypk1 is a substrate for purified TORC2 in vitro, we have not shown that the residues in Ypk1 subject to TORC2-mediated phosphorylation include these four new sites. It remains, therefore, a formal possibility that, in the cell, phosphorylation at one or more of these positions is mediated by a TORC2-dependent protein kinase rather than TORC2 itself. However, because TORC2 was the only Ser/Thr kinase that, when inactivated, abolished phosphorylation at these residues in vivo, they are very likely direct phospho-acceptor sites for TORC2. Consistent with that conclusion, the minimal consensus shared among the turn and hydrophobic motifs and the new sites is -S/T-Hpo-, where Hpo designates any hydrophobic residue bulkier than Ala. It is worth noting in this same regard that several other phosphorylation sites identified in our MS experiments also have a bulky hydrophobic residue at the +1 position, and phosphorylation at some of these sites (e.g., Thr57) was elevated after Myr treatment (data not shown). Although lack of phosphorylation at these sites did not cause any mobility shift on Phos-tag gels that we could monitor, we have not ruled out the possibility that these phosphorylation sites may nonetheless be under TORC2 control and/or direct targets of TORC2. In any event, we have demonstrated here that TORC2-mediated phosphorylation at S653, S671, S672, and S678 is necessary for full Ypk1 function. Taken together, the most parsimonious interpretation of our data is that TORC2 phosphorylates its preferred sites at the C terminus of Ypk1, perhaps sequentially, starting from the C terminus. Presumably, successive modification helps destabilize and peel back the C-terminal segment of the protein, making the next site more accessible, allowing TORC2 readier access to the hydrophobic motif and the turn motif, which, once modified, can then bind to and lock in the active conformation of the N-lobe of the kinase fold. In this way, phosphorylation of the four new sites allows for optimal phosphorylation of Ypk1 at its hydrophobic and turn motif, consistent with our finding that preventing phosphorylation of Ypk1 at the four C-terminal sites makes cells Myr sensitive and prevents hydrophobic motif phosphorylation. Likewise, loss of three of these sites (S653, S671, and S672) was also sufficient to confer Myr sensitivity and compromise Thr662 phosphorylation (data not shown), whereas retention of phosphorylation at even two of these sites permitted Ypk1 function. Several additional findings reinforce the conclusion that these new C-terminal sites are physiologically important. In our MS analysis, when cells were treated with Myr, in addition to elevation of S644 and T662 phosphorylation, we found a readily detectable increase in phosphorylation at the most proximal site (S653) (data not shown). In agreement with our observations, in a very recent global phospho-proteomics study, increased phosphorylation of Ypk1 at both S653 and S672 were observed following Myr treatment (Lebesgue ). Thus, it does appear that TORC2 responds to sphingolipid depletion by enhancing phosphorylation of Ypk1 at the four C-terminal sites, which, in turn, allows for efficient hydrophobic and turn motif phosphorylation. In a similar way, it has been reported that, in response to the stress of a nonphysiological concentration (10 mM) of exogenous methylglyoxal, phosphorylation of Pkc1, another AGC kinase in S. cerevisiae that is a target of TORC2 (Ho ; Kamada ), is increased at sites corresponding to its turn and hydrophobic motifs (Roelants ; Nomura and Inoue 2015). Moreover, lack of phosphorylation at the turn motif site (T1125 in Pkc1) reduces the efficiency of phosphorylation at the hydrophobic motif (S1143 in Pkc1) and vice versa (Nomura and Inoue 2015), reminiscent of the interdependencies we found for phosphorylation among the C-terminal sites in Ypk1. Modification of Ser644 in the turn motif is presumed to be under the control of TORC2. Indeed, in our MS study, we found an increase in Ser644 phosphorylation after Myr treatment (data not shown). Moreover, a Ypk1S644A-myc mutant was inviable even at the lowest concentrations of Myr tested and was even more sensitive to Myr than a Ypk1T662A-myc mutant. Thus, S644 phosphorylation is critical for Ypk1 function (although we could not readily monitor S644 phosphorylation by immunoblotting because, currently, a phospho-site-specific antibody that reliably reports this modification in Ypk1 is not available). Quite similarly, phosphorylation at the turn motif per se has been reported to be important for proper C-terminal folding and stability of mammalian AKT and PKC (Facchinetti ; Ikenoue ). In this regard, we also found that absence of phosphorylation at the four new C-terminal phosphorylation sites diminished the steady-state level of Ypk1 significantly, in further agreement with the model that TORC2-mediated phosphorylation at the four C-terminal sites promotes modification of Ser644 and the function of that modification is stabilizing Ypk1, as it does in the mammalian AGC kinases. In any event, collectively, our observations document that full TORC2-dependent phosphorylation of Ypk1 at six C-terminal sites (the four new sites and the turn and hydrophobic motifs) is necessary for optimal Ypk1 function. To date, there is no available crystal or NMR structure for Ypk1. There is a reported crystal structure at 1.9-Å resolution for a 431-residue splice variant of SGK1, the human ortholog of Ypk1 (Casamayor ), in a complex with an Mg2+-bound, nonhydrolyzable ATP analog (AMPPNP); however, in this structure, 59 N-terminal residues were deleted and 6 substitution mutations (S74A S78A R192A S397A S401A S422D) were introduced to “stabilize” the protein (Zhao ). Overall, the structure obtained most closely resembles the inactive conformations of other AGC kinases and the αC helix is totally absent (because it adopts, instead, a β-strand arrangement via formation of an antiparallel β-sheet with a portion of the sequence corresponding to the activation loop). Thus, the construct analyzed is of little utility for understanding authentic SGK1 function. Ypk1 contains a well-conserved kinase domain and a prominent N-terminal extension that is four times larger than its C-terminal extension. The exact function of the Ypk1 N-terminal domain is unknown, but several observations indicate that it serves a negative regulatory role. First, unlike overexpression of full-length Ypk1, overexpressing an N-terminally truncated Ypk1∆N mutant is toxic to cells, whereas overexpressing a kinase-dead derivative of the Ypk1∆N mutant is not (Roelants ). Second, as we showed before, a Ypk1 mutant with an N-terminal substitution mutation (D242A) rescues the inviability of a allele (Roelants ), suggesting that alteration of the N-terminal domain alleviates the need for TORC2-dependent phosphorylation of Ypk1. Third, we confirmed and solidified that conclusion by documenting here that the D242A mutation suppresses the loss-of-function phenotypes of Ypk1 mutants that cannot be phosphorylated at the hydrophobic motif, at the turn motif, and at all four of the new C-terminal sites. The simplest model to explain how the D242A point mutation bypasses the need for TORC2 phosphorylation is that, normally, the N-terminal domain interacts with and constrains the kinase fold in an inactive conformation and the role of the C terminus is to compete with and displace this N-terminal inhibitory domain, which the C terminus can only do effectively when it is phosphorylated. In the D242A mutant, the inhibitory role of the N-terminal domain is presumably crippled, allowing the kinase fold to more easily adopt its active conformation, even in the absence of TORC2-dependent phosphorylation of the C-terminal sites. A purely speculative model for how the negatively charged Asp242 residue in the N-terminal regulatory domain might exert its negative influence and compete with TORC2-mediated phosphorylation of the C-terminal sites is by specifically occupying a binding pocket lined with basic residues which can only be bound by the turn motif when it is phosphorylated, equivalent to the interaction revealed in the crystal structures of the activated states of several mammalian AGC kinase family members (Grodsky ; Hauge ). Thus, when such a critical D242-dependent salt bridge(s) is broken by mutation to Ala, the inhibitory constraint imposed by the N-terminal negative regulatory domain is relieved without the need for any competitive binding by phosphorylated C-terminal sites. Indeed, consistent with this speculative model, in otherwise WT Ypk1, mutation of either the four new C-terminal sites to Glu/Asp or the hydrophobic motif to Glu was sufficient to maintain full biological function, indicating that the presence of negatively charged residues in this region is sufficient to outcompete and overcome the inhibitory effect of the N-terminal domain. However, Ypk1D242A itself is clearly not hyperactive; stimulation of its TORC2-dependent phosphorylation by Myr treatment markedly increased Ypk1-mediated phosphorylation of an in vivo target (Orm1). Thus, negative charges at the C-terminal end (either authentic phosphate groups or a negatively charged amino acid side chain) are still needed, presumably to maximize interaction with and optimally stabilize the kinase domain in its active conformation, again akin to what is observed in the crystal structures of the activated state of AKT (Yang ,b) and other mammalian AGC kinases (Grodsky ; Hauge ). Indeed, mammalian AKT is phosphorylated in an mTORC2-dependent manner at C-terminal sites in addition to its turn and hydrophobic motifs (Liu ). Moreover, consistent with what we have observed for Ypk1, phosphorylation of AKT at its C terminus is necessary for efficient hydrophobic motif phosphorylation (Liu ). S. cerevisiae encodes a functional Ypk1 paralog, Ypk2 (Chen ; Roelants ). Reassuringly, in global phospho-proteomic studies (Holt ; Swaney ), sites of phosphorylation in Ypk2 have been reported that correspond to S653 and S672 in Ypk1, suggesting that Ypk2 is likely regulated by TORC2 in a manner similar to Ypk1. Moreover, a site equivalent to S678 in Ypk1 is also conserved in Ypk2. The only exception is that the residue corresponding to S671 in Ypk1 is already a negatively charged residue (Asp) in Ypk2 and is not conserved in three of the more distant Ypk1 orthologs, indicating that in all these enzymes the residue equivalent to S672 in Ypk1 is the important site for TORC2-dependent phosphorylation at this location. Interestingly, the residue in Ypk2 that corresponds to Ser672 in Ypk1 is followed by Pro, suggesting that Pro is among the hydrophobic residues that TORC2 is able to recognize at the position +1 to the phospho-acceptor residue. In S. cerevisiae, Sch9, another AGC-family protein kinase, is phosphorylated by TORC1 at multiple C-terminal positions in addition to the sites equivalent to its turn and hydrophobic motifs (Urban ). Just as we have shown here for TORC2-mediated phosphorylation of Ypk1, TORC1-mediated phosphorylation of Sch9 at these novel C-terminal sites also changes in response to stresses that are known to modulate TORC1 activity, such as carbon and nitrogen starvation (Urban ). Also, as with the new C-terminal sites we characterized in Ypk1, the TORC1 phosphorylation sites in Sch9 exhibit a preference for a hydrophobic (alkyl or aromatic) residue at the position +1 to the phospho-acceptor residue (Urban ), which may explain why either Tor1 or Tor2 can function in TORC1. Similarly, it has been reported that mTOR also prefers a hydrophobic (alkyl, including Pro, or aromatic) residue in the +1 position (Hsu ). In conclusion, our detailed analysis of yeast Ypk1 demonstrates that extensive C-terminal phosphorylation is a conserved mechanism by which TOR complexes regulate AGC-family protein kinases.
  81 in total

1.  Plasma membrane recruitment and activation of the AGC kinase Ypk1 is mediated by target of rapamycin complex 2 (TORC2) and its effector proteins Slm1 and Slm2.

Authors:  Brad J Niles; Huzefa Mogri; Andrew Hill; Ariadne Vlahakis; Ted Powers
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-17       Impact factor: 11.205

2.  Yeast/E. coli shuttle vectors with multiple unique restriction sites.

Authors:  J E Hill; A M Myers; T J Koerner; A Tzagoloff
Journal:  Yeast       Date:  1986-09       Impact factor: 3.239

Review 3.  TORC2 Structure and Function.

Authors:  Christl Gaubitz; Manoel Prouteau; Beata Kusmider; Robbie Loewith
Journal:  Trends Biochem Sci       Date:  2016-05-05       Impact factor: 13.807

4.  Methylglyoxal activates the target of rapamycin complex 2-protein kinase C signaling pathway in Saccharomyces cerevisiae.

Authors:  Wataru Nomura; Yoshiharu Inoue
Journal:  Mol Cell Biol       Date:  2015-01-26       Impact factor: 4.272

5.  Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast.

Authors:  J Heitman; N R Movva; M N Hall
Journal:  Science       Date:  1991-08-23       Impact factor: 47.728

6.  Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs.

Authors:  Janine Mok; Philip M Kim; Hugo Y K Lam; Stacy Piccirillo; Xiuqiong Zhou; Grace R Jeschke; Douglas L Sheridan; Sirlester A Parker; Ved Desai; Miri Jwa; Elisabetta Cameroni; Hengyao Niu; Matthew Good; Attila Remenyi; Jia-Lin Nianhan Ma; Yi-Jun Sheu; Holly E Sassi; Richelle Sopko; Clarence S M Chan; Claudio De Virgilio; Nancy M Hollingsworth; Wendell A Lim; David F Stern; Bruce Stillman; Brenda J Andrews; Mark B Gerstein; Michael Snyder; Benjamin E Turk
Journal:  Sci Signal       Date:  2010-02-16       Impact factor: 8.192

7.  Chemical genetics of rapamycin-insensitive TORC2 in S. cerevisiae.

Authors:  Joseph I Kliegman; Dorothea Fiedler; Colm J Ryan; Yi-Fan Xu; Xiao-Yang Su; David Thomas; Max C Caccese; Ada Cheng; Michael Shales; Joshua D Rabinowitz; Nevan J Krogan; Kevan M Shokat
Journal:  Cell Rep       Date:  2013-12-19       Impact factor: 9.423

8.  Sphingolipid biosynthesis upregulation by TOR complex 2-Ypk1 signaling during yeast adaptive response to acetic acid stress.

Authors:  Joana F Guerreiro; Alexander Muir; Subramaniam Ramachandran; Jeremy Thorner; Isabel Sá-Correia
Journal:  Biochem J       Date:  2016-09-26       Impact factor: 3.857

9.  Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression.

Authors:  J Kunz; R Henriquez; U Schneider; M Deuter-Reinhard; N R Movva; M N Hall
Journal:  Cell       Date:  1993-05-07       Impact factor: 41.582

10.  TOR Complex 2-Regulated Protein Kinase Fpk1 Stimulates Endocytosis via Inhibition of Ark1/Prk1-Related Protein Kinase Akl1 in Saccharomyces cerevisiae.

Authors:  Françoise M Roelants; Kristin L Leskoske; Ross T A Pedersen; Alexander Muir; Jeffrey M-H Liu; Gregory C Finnigan; Jeremy Thorner
Journal:  Mol Cell Biol       Date:  2017-03-17       Impact factor: 4.272

View more
  13 in total

Review 1.  Regulation of TORC2 function and localization by Rab5 GTPases in Saccharomyces cerevisiae.

Authors:  Melissa N Locke; Jeremy Thorner
Journal:  Cell Cycle       Date:  2019-05-15       Impact factor: 4.534

2.  TOR complex 2 is a master regulator of plasma membrane homeostasis.

Authors:  Jeremy Thorner
Journal:  Biochem J       Date:  2022-09-30       Impact factor: 3.766

3.  mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation.

Authors:  Joseph G Moloughney; Nicole M Vega-Cotto; Sharon Liu; Chadni Patel; Peter K Kim; Chang-Chih Wu; Danielle Albaciete; Cedric Magaway; Austin Chang; Swati Rajput; Xiaoyang Su; Guy Werlen; Estela Jacinto
Journal:  J Biol Chem       Date:  2018-09-10       Impact factor: 5.157

Review 4.  The TORC2-Dependent Signaling Network in the Yeast Saccharomyces cerevisiae.

Authors:  Françoise M Roelants; Kristin L Leskoske; Maria Nieves Martinez Marshall; Melissa N Locke; Jeremy Thorner
Journal:  Biomolecules       Date:  2017-09-05

Review 5.  Role of MCC/Eisosome in Fungal Lipid Homeostasis.

Authors:  Jakub Zahumensky; Jan Malinsky
Journal:  Biomolecules       Date:  2019-07-25

6.  Analysis of the roles of phosphatidylinositol-4,5-bisphosphate and individual subunits in assembly, localization, and function of Saccharomyces cerevisiae target of rapamycin complex 2.

Authors:  Maria Nieves Martinez Marshall; Anita Emmerstorfer-Augustin; Kristin L Leskoske; Lydia H Zhang; Biyun Li; Jeremy Thorner
Journal:  Mol Biol Cell       Date:  2019-04-10       Impact factor: 3.612

7.  TOR Complex 2- independent mutations in the regulatory PIF pocket of Gad8AKT1/SGK1 define separate branches of the stress response mechanisms in fission yeast.

Authors:  Emese Pataki; Luba Simhaev; Hamutal Engel; Adiel Cohen; Martin Kupiec; Ronit Weisman
Journal:  PLoS Genet       Date:  2020-11-02       Impact factor: 5.917

8.  TOR complex 2 (TORC2) signaling and the ESCRT machinery cooperate in the protection of plasma membrane integrity in yeast.

Authors:  Oliver Schmidt; Yannick Weyer; Simon Sprenger; Michael A Widerin; Sebastian Eising; Verena Baumann; Mihaela Angelova; Robbie Loewith; Christopher J Stefan; Michael W Hess; Florian Fröhlich; David Teis
Journal:  J Biol Chem       Date:  2020-07-01       Impact factor: 5.157

Review 9.  Nuclear Functions of TOR: Impact on Transcription and the Epigenome.

Authors:  R Nicholas Laribee; Ronit Weisman
Journal:  Genes (Basel)       Date:  2020-06-10       Impact factor: 4.096

10.  The Two-Component Response Regulator Ssk1 and the Mitogen-Activated Protein Kinase Hog1 Control Antifungal Drug Resistance and Cell Wall Architecture of Candida auris.

Authors:  Raju Shivarathri; Sabrina Jenull; Anton Stoiber; Manju Chauhan; Rounik Mazumdar; Ashutosh Singh; Filomena Nogueira; Karl Kuchler; Anuradha Chowdhary; Neeraj Chauhan
Journal:  mSphere       Date:  2020-10-14       Impact factor: 4.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.